Compare · ABBV vs AKRO
ABBV vs AKRO
Side-by-side comparison of AbbVie Inc. (ABBV) and Akero Therapeutics Inc. (AKRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and AKRO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV carries a market cap of $521.50B.
- Over the past year, ABBV is up 26.2% and AKRO is up 0.6% - ABBV leads by 25.5 points.
- ABBV has hit the wire 15 times in the past 4 weeks while AKRO has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 15 for AKRO).
- Company
- AbbVie Inc.
- Akero Therapeutics Inc.
- Price
- -
- -
- Market cap
- $521.50B
- -
- 1M return
- +4.12%
- +0.61%
- 1Y return
- +26.15%
- +0.61%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2019
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 15
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Akero Therapeutics Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Latest ABBV
- EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 40,619 shares at a strike of $101.75, sold $11,925,738 worth of shares (40,619 units at $293.60) and gifted 3,450 shares, decreasing direct ownership by 4% to 79,721 units (SEC Form 4)
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
- SEC Form 10-Q filed by AbbVie Inc.
- Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
- AbbVie Inc. filed SEC Form 8-K: Leadership Update
- Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Third-Quarter 2026 Financial Results
- AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial
- The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
Latest AKRO
- NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
- SEC Form 15-12G filed by Akero Therapeutics Inc.
- SEC Form 25-NSE filed by Akero Therapeutics Inc.
- Director Heyman Tomas J. returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Xu Yuan returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)
- President and CEO Cheng Andrew returned 436,837 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Harrison Seth Loring returned 293,762 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Graham G. Walmsley returned 1,302,398 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Judy Chou returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Rolph Timothy returned 282,149 shares to the company, closing all direct ownership in the company (SEC Form 4)